Version 1.0.3

Submission

Home > Submission

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	02/01/2017
Deadline Date	30/01/2017
Date Submitted	25/01/2017
Type	Historic Performance in Initiating
NHS provider	Maidstone and Tunbridge Wells NHS Trust

Showing records 1 to 25 of 26.
Pages: 1 2 Next >

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Site Invited	Date Site Selected	HRA Approval Date
95710	13/NW/0501	123836	HRA Approval	QUAZAR CC-486-AML-001: A Phase 3, ramdomized, double-blind, placebo-controlled study to compare efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in subjects with acute myeloid Leukemia in			Yes	22/11/2016				114	201	315	No	12/01/2016	12/01/2016	25/04/2016
95711	14/EM/0172	142310	NHS Permission	BABY OSCAR- Outcome after Selective early Treatment for Closure of patient Ductus Arteriosus in Pre-term babies.	13/10/2015	12/02/2016	No		122						No			
				CARDAMON Carfilzomib/Cyclophosphamide/Dexamethasone														

95712	15/LO/0023	148600	HRA Approval	with maintenance carfilzomib in untreated trasnplant-eligible patients with symptomatic MM to evaluate the benefit of upfront ASCT			No					68			No	09/03/2016	27/07/2016	15/06/201€
95713	16/EM/0165	203281	HRA Approval	AP26113-13-301 A phase 3 multicentre open-label study of Brigatinib (AP26113) versus Crizotinib in patients with ALK-positive advanced lung cancer			No					108			No	18/04/2016	18/07/2016	10/06/201€
95714	16/SC/0351	205155	HRA Approval	GO30182 - A Phase III, open-label, multicentre, theree-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs regorafenib in patients with previously treated unresectable locally advan			No					67			No	15/06/2016	23/09/2016	31/08/201€
95715	15/EM/0473	187844	HRA Approval	Bayer 94-9343 / 15743 : A randomized, open-label, active-controlled, Phase 2 study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progres			Yes	30/11/2016				112	92	204	No	17/02/2016	10/05/2016	15/07/201€
95716	15/WM/0457	195511	NHS Permission	DARATUMUMAB: An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Mulitple Muyeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteas	02/03/2016	10/03/2016	Yes	22/03/2016	8	12	20				Yes			
95717	15/LO/1807	187302	NHS Permission	Checkmate 331 An Open-label, Randomized, Phase 3 study of Nivolumab or chemotherapy in subjects with replases small-cell lung cancer after Platinum- Based first line chemotherapy. CA209-331	25/01/2016	23/02/2016	Yes	20/07/2016	29	148	177				No			
95718	14/YH/1056	147421	HRA Approval	AB10004 Study- A Multicenter, Randomised, Open-label, three-parallel groups, phase 2-3 study to evuate the effiency and safety of masitinib with dexamenthasone, gemcitabine with dexamethasone and the combination of mastinib, gemcitabine and dexamethasone			No					95			No	21/10/2015	21/03/2016	21/06/201€
95719	15/LO/1419	183975	NHS Permission	PEARLS: A randomised, phase 3 trial with anti-PD-2 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy	21/03/2016	21/04/2016	Yes	18/01/2017	31	272	303				No			

95720	15/EE/0326	185205	NHS Permission	Seattle Genetics: SGN35-023 A randomised, open label, phase 2 study of rituximab and bendamustine with or without brentuximab vedotin for relapsed or refractory CD30-positive diffuse large B-cell lymphoma	23/03/2016	04/04/2016	No		12						No			
95721	14/SS/1043	142447	NHS Permission	UNIRAD: Randomized, doubled-blind, multicentre phase 111 trail evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2 - primary breast cancer who remain free of disease after receiving	06/03/2016	09/03/2016	Yes	21/11/2016	3	257	260				No			
95722	15/SC/0409	183061	NHS Permission	Safety and efficacy of Abicipar Pegol in Patients with neovascula age related macular degeneration	22/01/2016	17/11/2016	No		300						No			
95723	15/EM/0344	183906	NHS Permission	MORAb-009-201 A randomised, double-blind, place-controlled study of the safety and efficacy of amatuximab in combination with pemetrexed and cisplatin in subjects with unresectable malignant pleural mesothelioma	14/03/2016	23/03/2016	Yes	19/07/2016	9	118	127				No			
95724	15/WS/0011	122822	HRA Approval	BALLAD: A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma			No					12			No	05/03/2015	27/05/2016	29/04/2016
95725	13/NW/0153	104669	NHS Permission	CIPHER: Phase 11 multicentre study assessing the efficacy of Cabazitaxel in patients with HER2-negative metastatic breast cancer and having un-resectable brain metastases.	16/02/2016	23/02/2016	No		7						No			
95726	15/LO/0539	166304	HRA Approval	RAIDER - A Randomised phase 11 trial of Adaptive Image guided standard or Dose Escalated tumour boost Radiotherapy in the treatment of transitional cell carcinoma of the bladder			No					196			No	25/06/2015	24/03/2016	26/07/2016
95727	15/EM/0400	178129	NHS Permission	SOPHIA - A Phase 3, Randomised Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+Metastatic	16/02/2016	25/02/2016	Yes	22/11/2016	9	271	280				No			

				Breast Cancer Who Have Received Two Prior Anti-HER2 therapies and Require Systemic Treatment														
95728	16/YH/0154	202759	HRA Approval	DOMPERIDONE JNJ-17296812: A multicenter, double-blind, randomised, Placebo-controlled, parallel-group, Prospective Study to Evaluate the Safety and Efficiency of Domperidone in 6 month old to 12 year old Pediatric Subjects with Nausea and Vomiting due to			No					147			No	26/11/2015	07/04/2016	26/08/2016
95729	16/LO/0092	194133	NHS Permission	GO29834 - Harmony: A phase Ib/II study evaluating the safety and efficacy of Obinutuzumab in combination with Polatuzamab vedotin and lenalidomide in patients with relapsed or refractory follicular or diffucse large B-cell lumphoma.	21/03/2016	21/09/2016	No		184						No			
95730	15/LO/2110	136376	NHS Permission	All Polyethylene Versus Metal Backed Tibial Components in Knee Replacement - A Comparison Study	13/06/2016	16/06/2016	No		3						No			
95731	16/LO/0075	191435	HRA Approval	A prospective, multicentre, randomised trial: The effect of catheter valve Vs. standard catheter removal in outpatient settings on the patient discharge timings			Yes	09/01/2017				80	143	223	No	23/03/2016	31/05/2016	07/07/2016
				HART Hughes Abdominal Repair Trial -														

95732	12/WA/0374	98726	NHS Permission	Abdominal wall closure techniques to reduce incidence of incisional hernias	18/02/2016	23/02/2016	Yes	01/05/2016	5	68	73				No			
95733	14/NE/1176	16188	NHS Permission	UK Frost- Multi-center randomised controlled trial with Economic evaluation nested qualiative study comparing early structured physiotherapy verses manipulation under anaesthesia vs arthroscopic capsualr release for patients referred to secondary care wit	02/08/2016	06/09/2016	No		35						No			
95734	15/SC/0090	171171	NHS Permission	EndoPredict: The use of a prognostic tool (EndoPredict) to inform adjuvant chemotherapy decisions in low to medium risk Oestrogen Receptor Positive, Her-2 Negative Early Breast cancer: Feasibility, Acceptability and Economic impact in Multicentre UK NHS P	24/12/2015	15/01/2016	Yes	04/05/2016	22	110	132				No			

Showing records 1 to 25 of 26.
Pages: 1 2 Next >

< Back